- Home
- MNMD
as 01-17-2025 4:00pm EST
Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 519.2M | IPO Year: | N/A |
| Target Price: | $28.75 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.49 - $12.22 | Next Earning Date: | 02-26-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Mind Medicine (MindMed) Inc. (MNMD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sullivan Mark | MNMD | Chief Legal Officer | Dec 26 '24 | Sell | $7.43 | 4,519 | $33,576.17 | 173,197 | |
| Barrow Robert | MNMD | Chief Executive Officer | Dec 26 '24 | Sell | $7.43 | 19,106 | $141,957.58 | 526,666 | |
| Karlin Dan | MNMD | Chief Medical Officer | Dec 26 '24 | Sell | $7.43 | 6,643 | $49,357.49 | 338,013 | |
| Liao Carrie | MNMD | Chief Accounting Officer | Dec 26 '24 | Sell | $7.43 | 2,273 | $16,888.39 | 97,270 | |
| GRYSKA DAVID W | MNMD | Director | Dec 5 '24 | Buy | $7.17 | 2,500 | $17,925.00 | 19,851 |
Latest Mind Medicine (MindMed) Inc. News
MNMD Breaking Stock News: Dive into MNMD Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
MindMed to Be Added to the Nasdaq Biotechnology Index
Business Wire
a month ago
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
Business Wire
a month ago
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
Business Wire
a month ago
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
Business Wire
2 months ago
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy
Business Wire
2 months ago
MindMed Announces New Employee Inducement Grants
Business Wire
2 months ago
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
Simply Wall St.
2 months ago
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) market cap touched US$601m last week, benefiting both retail investors who own 41% as well as institutions
Compare MNMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MNMD Mind Medicine (MindMed) Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.